

## DESCRIPTION

Source	Human embryonic kidney cell, HEK293-derived human TGF-beta RI/ALK-5 protein			
	Human TGF-beta R1/ALK-5 (Ala25 or Leu34-Glu125) Accession # P36897.1	IEGRMD	Human IgG <sub>1</sub> (Pro100-Lys330)	Avi-tag
	N-terminus		C-terminus	
N-terminal Sequence Analysis	Ala25, Leu34			
Structure / Form	Disulfide-linked homodimer			
Predicted Molecular Mass	39 kDa			

## SPECIFICATIONS


<b>SDS-PAGE</b>	43-60 kDa, under reducing conditions
<b>Activity</b>	The biotin to protein ratio is greater than 0.7 as determined by the HABA assay.  Measured by its binding ability in a functional ELISA. When Recombinant Human (rh) TGF- $\beta$ RII Fc Chimera (Catalog # <a href="#">341-BR</a> ) is immobilized at 1 $\mu$ g/mL (100 $\mu$ L/well), in the presence of rhTGF- $\beta$ 1 (Catalog # <a href="#">240-B</a> ), Biotinylated Recombinant Human TGF- $\beta$ RI/ALK-5 Fc Chimera Avi-tag protein binds with an ED <sub>50</sub> of 0.15-0.75 $\mu$ g/mL.
<b>Endotoxin Level</b>	<0.10 EU per 1 $\mu$ g of the protein by the LAL method.
<b>Purity</b>	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

## PREPARATION AND STORAGE


<b>Reconstitution</b>	Reconstitute at 500 $\mu$ g/mL in PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> <li>12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>3 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## DATA

### SDS-PAGE



### SDS-PAGE



## BACKGROUND

TGF- $\beta$  RI, also called ALK-5, is an approximately 55 kDa type I transmembrane serine/threonine receptor kinase (1, 2). It contains a cysteine-rich extracellular domain (ECD), a transmembrane helix, and a C-terminal cytoplasmic kinase domain (3). Within the cytoplasmic domain there is also a short, conserved regulatory sequence known as the GS region that is N-terminal to the kinase domain (1). Within the ECD, human TGF- $\beta$  RI shares 90% and 88% aa sequence identity with mouse and rat TGF- $\beta$  RI, respectively. In the presence of TGF- $\beta$ , TGF- $\beta$  RI forms a complex with, and is phosphorylated by, TGF- $\beta$  RII (1). Phosphorylated TGF-beta RI can then transiently bind and phosphorylate Smad2 and Smad3 (2, 4-6). These phosphorylated Smads form heteromeric complexes with Smad4, translocate to the nucleus, and regulate target gene transcription (2, 4-6). TGF- $\beta$  RI is likely important during development, since mice deficient for TGF- $\beta$  RI die at midgestation with severe defects in vascular development of the yolk sac and placenta, and an absence of circulating red blood cells (7). Furthermore, TGF- $\beta$  RI appears to be involved in proper lymphatic network development (8). Mutations in TGF-beta RI have been identified in pancreatic, colorectal, ovarian, and head and neck cancers (9). Our Avi-tag Biotinylated human TGF- $\beta$  RI features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

## References:

1. Wrana, J.L. *et al.* (1994) *Nature* **370**:341.
2. Massagué, J. (2012) *Nat. Rev. Mol. Cell Biol.* **13**:616.
3. Huse, M. *et al.* (1999) *Cell* **96**:425.
4. Marcías-Silva, M. *et al.* (1996) *Cell* **87**:1215.
5. Zhang, Y. *et al.* (1996) *Nature* **383**:168.
6. Huse, M. *et al.* (2001) *Mol. Cell* **8**:671.
7. Larsson, J. *et al.* (2001) *EMBO J.* **20**:1663.
8. James, J.M. *et al.* (2013) *Development* **140**:3903.
9. Sheen, Y.Y. *et al.* (2013) *Biomol. Ther. (Seoul)* **21**:323.